The quality of reporting in published cost-utility analyses, 1976-1997

Annals of Internal Medicine

Volumn 132, Issue 12, 2000, Pages 964-972

  Neumann, Peter J ^a   Stone, Patricia W ^b   Chapman, Richard H ^a   Sandberg, Eileen A ^a   Bell, Chaim M ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA BASE; ECONOMIC EVALUATION; FINANCIAL MANAGEMENT; HEALTH CARE QUALITY; MEDICAL AUDIT; MEDICAL LITERATURE; PEER REVIEW; PRIORITY JOURNAL; PUBLICATION; QUALITY ADJUSTED LIFE YEAR;

EID: 0034691272     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-12-200006200-00007     Document Type: Article

References (43)

1. Elixhauser A, Halpern M, Schmier J, Luce BR. Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care. 1998;36(5 Suppl): MS1-9, MS18-147.
2. Elixhauser A, Luce BR, Taylor WR, Reblando J. Health care CBA/CEA: an update on the growth and composition of the literature. Med Care. 1993; 31(7 Suppl):JS1-11, JS18-149.
3. Russell LB, Gold MR, Siegel JE, Daniels N. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness Analysis in Health and Medicine. JAMA. 1996;276:1172-7.
4. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1253-8.
5. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276:1339-41.
6. Drummond MF, Richardson WS, O'Brien BJ, Levine M, Heyland D. Users' guides to the medical literature. XIII How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 1997;277;1552-7.
7. O'Brien BJ, Heyland D, Richardson WS, Levine M, Drummond MF. Users' guides to the medical literature. XIII. How to use an article on economic analysis in clinical practice. B. What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA. 1997;277:1802-6.
8. Udvarhelyi IS, Colditz GA, Rai A, Epstein AM. Cost-effectiveness and cost-benefit analyses in the medical literature. Are they being used correctly? Ann Intern Med. 1992;116:238-44.
9. Kassirer J, Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med. 1994;331:669-70.
10. Evans RG. Manufacturing consensus, marketing truth: guidelines for economic evaluation [Editorial]. Ann Intern Med. 1995;123:59-60.
11. Neumann PJ, Zinner DE, Wright JC. Are methods for estimating QALYs in cost-effectiveness analyses improving? Med Decis Making. 1997;17:402-8.
12. Luce BR, Lyles AC, Rentz AM. The view from managed care pharmacy. Health Aff (Millwood). 1996;15:168-76.
13. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996.
14. Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford Univ Pr; 1987.
15. Jefferson TO, Smith R, Yee Y, Drummond MJ, Pratt M, Gale R. Evaluating the BMJ guidelines for economic submissions. JAMA. 1998;280:275-7.
16. Mehrez A, Gafni A. Healthy-years equivalents versus quality-adjusted life years: in pursuit of progress. Med Decis Making. 1993;13:287-92.
17. Cox D, Fitzpatrick R, Fletcher A, Gore S, Spiegelhalter D, Jones D. Quality-of-life assessment: can we keep it simple? J R Statist Soc A. 1992; 155:353-93.
18. Ubel PA, Loewenstein G, Scanlon D, Kamlet M. Individual utilities are inconsistent with rationing choices. A partial list of why Oregon's cost-effectiveness list failed. Med Decis Making. 1996;16:108-16.
19. Menon D, Schubert F, Torrance GW. Canada's new guidelines for the economic evaluation of pharmaceuticals. Med Care. 1996;34:DS77-86.
20. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. 2d ed. New York: Oxford Univ Pr; 1997.
21. Economic analysis of health care technology. A report on principles. Task Force on Principles for Economic Analysis of Health Care Technology. Ann Intern Med. 1995;123:61-70.
22. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ. 1996;313:275-83.
23. Landis RJ, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159-74.
24. Gerard K, Smoker I, Seymour J. Raising the quality of cost-utility analyses: lessons learnt and still to learn. Health Policy. 1999;46:217-38.
25. Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force. 2d ed. Baltimore: Williams & Wilkins; 1996.
26. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369-90.
27. Gerard K. Cost-utility in practice: a policy maker's guide to the state of the art. Health Policy. 1992;21:249-79.
28. Brown ML, Fintor L. Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature. Breast Cancer Res Treatment. 1993;25:113-8.
29. Nord E. Toward quality assurance in QALY calculations. Int J Technol Assess Health Care. 1993;9:37-45.
30. Mason JM. Cost-per-QALY league tables: their role in pharmacoeconomic analysis. Pharmacoeconomics. 1994;5:472-81.
31. Adams ME, McCall NT, Gray DT, Orza MJ, Chalmers TC. Economic analysis in randomized controlled trials. Med Care. 1992;30:231-43.
32. Briggs A, Sculpher M. Sensitivity analysis in economic evaluation: a review of published studies. Health Econ. 1995;4:355-71.
33. Blackmore CC, Magid DJ. Methodologic evaluation of the radiology cost-effectiveness literature. Radiology. 1997;203:87-91.
34. Balas EA, Kretschmer RA, Gnann W, West DA, Boren SA, Center RM, et al. Interpreting cost analyses of clinical interventions. JAMA. 1998;279: 54-7.
35. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practice. N Engl J Med. 1977;296:716-21.
36. Graham JD, Corso PS, Morris JM, Segui-Gomez M, Weinstein MC. Evaluating the cost-effectiveness of clinical and public health measures. Annu Rev Public Health. 1998;19:125-52.
37. Reinhardt UE. Making economic evaluations respectable. Soc Sci Med. 1997;45:555-62.
38. Elstein AS. MDM policy regarding financial support of authors. Med Decis Making 1997;17:497-8.
39. Paltiel AD, Neumann PJ. Why training is the key to successful guideline implementation. Pharmacoeconomics. 1997;12:297-302.
40. Neumann PJ. Paying the piper for pharmacoeconomic studies. Med Decis Making. 1998;18(2 Suppl):S23-6.
41. Neumann PJ, Zinner DE, Paltiel AD. The FDA's regulation of cost-effectiveness claims. Health Aff (Millwood). 1996;15:54-71.
42. Mitchell A. Update and evaluation of Australian guidelines. Government perspective. Med Care. 1996;34(12 Suppl):DS216-25.
43. OHE Briefing. The Health Economic Evaluations Database. Trends in Economic Evaluation. London: OHE-IFPMA; 1998.